基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Bob Anderson MBChB BMedSc PhD FRACP AGAF
Bob graduated in medicine and then completed a PhD supervised by Vint Chadwick in experimental medicine from the University of Otago in New Zealand. His specialist training in adult gastroenterology was in Melbourne, Australia at The Royal Melbourne Hospital and St Vincent's Hospital. This was followed by a 4-year post-doc as an NHMRC Robert Menzies Fellow at Oxford University supervised by Derek Jewell and Adrian Hill. His work there drew on vaccinology approaches to understand the specificity of T cells responding to gluten in patients with coeliac disease. This work and his subsequent research have pioneered novel approaches to first demonstrate and measure the recall immune response to gluten in blood. Bob returned to Melbourne in 2002, and established a coeliac disease research program as a lab head in the Immunology Division at the Walter and Eliza Hall Institute. During this period he led the designing of Nexvax2, the first antigen-specific immunotherapy for coeliac disease to enter clinical development. Bob guided the preclinical and first in human testing in patients in his roles as Chief Scientific Officer and later Chief Executive Officer of Nexpep Pty Ltd. Bob moved to Cambridge Massachusetts in 2012, and continued the clinical development of Nexvax2 as Chief Scientific Officer at ImmusanT until 2019. He returned to Australia in January 2020. He practices in gastroenterology at Mackay Base Hospital in Queensland, and consults for biopharma companies developing therapies for coeliac disease. He co-founded Brisbane-based Novoviah Pharmaceuticals in 2020 to continue development of peripheral blood diagnostics for T-cell mediated diseases including coeliac disease, and also therapeutics for gut immune diseases. Bob was elected President of the International Society for the Study of Coeliac Disease in October 2022. The 2023 Celiac Disease Foundation Prize in Excellence in Celiac Disease Research was awarded to Bob for his research in patients with celiac disease that has helped to cement the role of gluten-reactive T cells as the fundamental drivers of celiac disease.
Research Interests
Papers共 136 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Gastroenterologyno. 1 (2024): 183-193
Martina Crepaldi, Michela Palo, Daria Maniero, Luisa Bertin, Edoardo Vincenzo Savarino,Robert P. Anderson, Fabiana Zingone
PHARMACEUTICALSno. 1 (2024): 4
The lancet. Gastroenterology & hepatologyno. 5 (2023): 446-457
Journal of the Canadian Association of Gastroenterologyno. Supplement_1 (2023): 4-4
ALIMENTARY PHARMACOLOGY & THERAPEUTICSno. 5 (2021): 654-655
Load More
Author Statistics
#Papers: 138
#Citation: 5330
H-Index: 36
G-Index: 72
Sociability: 6
Diversity: 0
Activity: 1
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn